GREENLAND MINES LTD Underwriting Expense Ratio
GREENLAND MINES LTD (GRML) reported Underwriting Expense Ratio of 2.50% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:UnderwritingExpenseRatio · last filed 2023-11-17
- GREENLAND MINES LTD underwriting expense ratio for the quarter ending 2023-03-31 was 2.50%, a 0.00% change year-over-year.
- GREENLAND MINES LTD underwriting expense ratio for the quarter ending 2022-03-31 was 2.50%.
- GREENLAND MINES LTD underwriting expense ratio for fiscal 2022 was 2.50%.
| Period end | Underwriting Expense Ratio 3 month | Underwriting Expense Ratio 6 month | Underwriting Expense Ratio 9 month | Underwriting Expense Ratio 12 month |
|---|---|---|---|---|
| 2023-09-30 | 2.50% 10-Q · filed 2023-11-17 | |||
| 2023-06-30 | 2.50% 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | 2.50% 10-Q · filed 2023-05-24 | |||
| 2022-12-31 | 2.50% 10-K/A · filed 2023-10-18 | |||
| 2022-09-30 | 2.50% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 2.50% 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 2.50% 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |